Pharmacokinetics of lamivudine administered alone and with trimethoprim-sulfamethoxazole

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 5, 1996, Pages 550-558

  Moore, Katy H P ^a   Yuen, Geoffrey J ^a   Raasch, Ralph H ^a   Eron, Joseph J ^a   Martin, David ^a   Mydlow, Patricia K ^a   Hussey, Elizabeth K ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; LAMIVUDINE; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; FEMALE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; ZALCITABINE;

EID: 0029900659     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90183-6     Document Type: Article

References (27)

1. Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N Engl J Med 1987;317:192-7.
2. Coates JAV, Gammack N, Jenkinson HJ, et al. The separated enantiomers of 2′-deoxy-3′-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother 1992;36:202-5.
3. Coates JAV, Gammack N, Jenkinson HJ, et al. (-)-2′-Deoxy-3′-thiacytidine (lamivudine) is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother 1992;36:733-9.
4. Schinazi RF, Chu CK, Peck A, et al. Activities of four optical isomers of 2′,3′-dideoxy-3′-thiacytidine (BCH 189) against human immunodeficiency virus type 1 in human lymphocytes. Antimicrob Agents Chemother 1992;36:1688-94.
5. Kemp SD, Harrigan PR, Kinghorn I, Kohli A, Larder BA. Antiviral potency of AZT + 3TC combination therapy in vivo supports in vitro virological observations [Abstract]. AIDS 1994;8:S4.
6. Eron JJ, Benoit SL, Jemsek J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
7. Cammack N, Rouse P, Marr CLP, et al. Cellular metabolism of (-) entantiomeric 2′-deoxy-3′-thiacytidine. Biochem Pharmacol 1992;43:2059-64.
8. van Leeuwen R, Lange JMA, Hussey EK, et al. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS 1992;6:1471-5.
9. Horton CM, Yuen G, Mikolich DM, et al. Pharmacokinetics (PK) of oral lamivudine administered alone and with oral zidovudine (ZDV) in asymptomatic patients with human immunodeficiency virus (HIV) infection [Abstract]. Clin Pharmacol Ther 1994;55:198.
10. Yuen GJ, Morris DM, Mydlow PK, Haidar S, Hall ST, Hussey EK. The pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine. J Clin Pharmacol 1995;35:1174-80.
11. Pluda JM, Cooley TP, Montaner JSG, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis 1995;171:1438-47.
12. Sweeney KR, Hsyu PH, Statkevich P, Taft D. The renal disposition of lamivudine (3TC) in the isolated perfused rat kidney (IPK) [Abstract]. Pharm Res 1993;10:S368.
13. Harker AJ, Evans GL, Hawley AE, Morris DM. High-performance liquid chromatographic assay for 2′-deoxy-3′-thiacytidine in human serum. J Chromatogr 1994;65:227-32.
14. Morris DM, Selinger K. Determination of 2′-deoxy-3′-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching. J Pharm Biomed Anal 1994;12:255-64.
15. Gochin R, Kanfer I, Haigh JM. Simultaneous determination of trimethoprim, sulfamethoxazole and N4-acetylsulfamethoxazole in serum and urine by high-performance liquid chromatography. J Chromtogr 1981;223:139-45.
16. Gibaldi M, Perrier D, ed. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982:45-111.
17. Riegelman S, Collier P. The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 1980;8:509-34.
18. Conover WJ. Practical non-parametric statistics. 2nd ed. New York: John Wiley, 1980:223-7, 288-90.
19. Koch GG. The use of non-parametric methods in the statistical analysis of the two-period change-over design. Biometrics 1972;28:577-84.
20. Stevens RC, Laizure SC, Williams CL, Stein DS. Pharmacokinetics and adverse effects of 20 mg/kg/day trimethoprim and 100 mg/kg/day sulfamethoxazole in healthy adult subjects. Antimicrob Agents Chemother 1991;35:1884-90.
21. Stevens RC, Laizure SC, Sanders PL, Stein DS. Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother 1993;37:448-52.
22. Lamivudine package insert. Glaxo Wellcome, Inc. 1995.
23. Chatton JY, Munafo A, Chave JP, et al. Trimethoprim, alone or in combination with sulfamethoxazole, decreases the renal excretion of zidovudine and its glucuronide. Br J Clin Pharmacol 1992;34:551-4.
24. Cacini W. In vivo renal tubular secretion of trimethoprim without metabolism. Biochem Pharmacol 1987;36:2693-5.
25. Cacini W, Myrc SA. Uptake of trimethoprim by renal cortex. Biochem Pharmacol 1985;34:3483-8.
26. de Miranda P, Good SS, Yarchoan R, et al. Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther 1989;46:494-500.
27. Kaplan JE, Masur H, Holmes KK, et al. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: an overview. Clin Infect Dis 1995;21(suppl 1):12-31.